The estimated Net Worth of Charles A Dinarello is at least $2.26 Milion dollars as of 8 August 2018. Charles Dinarello owns over 5,000 units of Bio-Techne Corp stock worth over $970,950 and over the last 19 years Charles sold TECH stock worth over $1,290,420.
Sign up
Charles Dinarello TECH stock SEC Form 4 insiders trading
Charles has made over 10 trades of the Bio-Techne Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Charles exercised 5,000 units of TECH stock worth $315,150 on 8 August 2018.
The largest trade Charles's ever made was exercising 5,000 units of Bio-Techne Corp stock on 8 August 2018 worth over $315,150. On average, Charles trades about 1,780 units every 57 days since 2005. As of 8 August 2018 Charles still owns at least 13,212 units of Bio-Techne Corp stock.
You can see the complete history of Charles Dinarello stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Dinarello's mailing address?
Charles's mailing address filed with the SEC is 333 15th St, Boulder, CO 80302, USA.
Insiders trading at Bio-Techne Corp
Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey a John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.
What does Bio-Techne Corp do?
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
What does Bio-Techne Corp's logo look like?
Complete history of Charles Dinarello stock trades at Bio-Techne Corp
Bio-Techne Corp executives and stock owners
Bio-Techne Corp executives and other stock owners filed with the SEC include:
-
Charles Kummeth,
President, Chief Executive Officer, Director -
Charles R. Kummeth,
CEO, Pres & Director -
James Hippel,
Chief Financial Officer, Executive Vice President - Finance -
David Eansor,
President - Protein Sciences -
Kim Kelderman,
President - Diagnostics and Genomics -
Brenda Furlow,
Senior Vice President, General Counsel, Corporate Secretary -
James T. Hippel,
Exec. VP of Fin. & CFO -
Norman David Eansor,
Pres of Protein Sciences Segment -
Kim Kelderman,
Pres of Diagnostics & Genomics -
Brenda S. Furlow J.D.,
Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Robert Baumgartner,
Independent Chairman of the Board -
Rupert Vessey,
Independent Director -
John Higgins,
Independent Director -
Randolph Steer,
Independent Director -
Roeland Nusse,
Independent Director -
Alpna Seth,
Independent Director -
Joseph Keegan,
Independent Director -
David Clair,
IR Contact Officer -
Julie Bushman,
Independent Director -
Kevin Smyth,
Sr. VP & Chief Digital Officer -
Luca Cicchetti,
Managing Director -
Brenda Everson,
Sr. VP of HR -
Kevin S. Gould,
Sr. VP of Diagnostics Reagents Division -
Struan Robertson,
VP of HR -
Robert M. Gavin,
VP of Corp. Devel. -
Gerry Andros,
VP of Sales and Marketing -
Karen A Holbrook,
Director -
Roger C Lucas,
-
Charles A Dinarello,
-
J. Fernando Bazan,
Chief Technical Officer -
Robert M. Gavin,
Sen. VP Protein Platforms -
Kevin S Gould,
SVP Clinical Controls -
Kevin J Reagan,
Senior VP Biotech -
Gregory J Melsen,
VP Finance and CFO -
Thomas E Oland,
President -
Howard V Oconnell,
Director -
Marcel Veronneau,
Vice Pres-Hematology Oper. -
James A Weatherbee,
Chief Scientific Officers -
Monica Tsang,
Vice President of Research -
Christopher S Henney,
Director -
G A Herbert,
Director -
Harold J Wiens,
-
William Geist,
PRESIDENT, PROTEIN SCIENCES -
Shane Bohnen,
SVP - General Counsel -
Matthew Mc Manus,
President - DGS -
Judith V Klimovsky,
Director